← Back to Investor Relations
In the Press
Helio Genomics Announces New HelioLiver Access Through Quest
Why This Matters
FinanceWire extends the Business Insider coverage into financial wire services monitored by institutional investors and analysts, reinforcing Helio's presence across multiple layers of the financial media ecosystem.
Article Summary
FinanceWire reports that Helio Genomics will make HelioLiver available through Quest Diagnostics starting April 2026. The article details how the test combines cell-free DNA methylation patterns, protein biomarkers, and patient demographics through a proprietary AI algorithm to detect hepatocellular carcinoma. Testing remains centralized at Helio's CLIA-certified laboratory in West Lafayette, Indiana, with sample collection supported by Quest's 7,700 patient service locations.